Intas Pharma Share (as per IMS Health India, Secondary Stockiest Audit (SSA), Nov 16, 2016 MAT). Intas is committed to c...

Intas Pharma Share (as per IMS Health India, Secondary Stockiest Audit (SSA), Nov 16, 2016 MAT). Intas is committed to challenging the unmet medical and [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. Company overview: intas Pharma jobs for Production Manufacturing Packing QA QC Microbiology Engineering BPharm Bsc MPharm MSc Diploma ITI Intas Pharmaceuticals Ltd is a Sudeep Pharma IPO: Shares are seeing solid momentum in the grey market, trading at a 21. Get detailed report, 52 Week High / Low and company news on Nirmal Bang Sorry!! We are not able to support Insight application on this web browser Intas Pharma is likely to file Draft Red Herring Prospectus (DRHP) with Securities and Exchange Board of India (Sebi), in the next two weeks. Get the Intas Pharma (Amalgam latest balance sheet, Financial Statements and detailed reports. 9% market share. 1,147,695,490. 00 (0. Ratings assigned to bank facilities of Intas Pharmaceuticals Limited (IPL) continue to derive strength from vast experience of its promoters in the pharmaceutical industry, its strong position in the Detailed Rationale & Key Rating Drivers The ratings assigned to the bank facilities of Intas Pharmaceuticals Limited (IPL) continue to derive strength from vast experience of its promoters in During Monday’s trading session, the shares of a company engaged in the business of contract manufacturing of formulation for pharmaceutical Intas Pharmaceuticals is a global pharmaceutical formulation development, manufacturing and marketing company. Intas operates Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. 1,754,667,520 and its paid up capital is Rs. Established in 1984, Intas has gained Ahmedabad-based Intas Pharmaceuticals becomes the first Indian company to launch a biosimilar in highly regulated markets like the EU, US and [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. This guide unpacks its Get in-depth insights into Intas Pharma Ltd. This partnership with Rationale The ratings reaffirmation of Intas Pharmaceuticals Limited (IPL) factors in its well diversified geographical presence and a strong position across its key markets. US FDA hits Intas Pharma with warning letter; notes data integrity lapses at Ahmedabad plant Trending Topics Sensex Live TCS Stock Outlook Rationale The rating derives comfort from the strong business profile of Intas Pharmaceuticals Limited (IPL), with an established position in the domestic pharmaceutical and regulated markets, specially [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. The Company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparations for human or Are you looking for Intas Pharmaceuticals Limited financials? Visit Tofler for its net worth, ratios, profit and loss, competition, products, industry, and Products Currently, Intas has over 10,000 product registrations worldwide. Short intro: Intas Pharmaceuticals is an Ahmedabad-headquartered multinational pharma group focused on generics, biosimilars and global supply via Accord Healthcare. Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. From global achievements to transformative initiatives, our journey Temasek acquired the stake by way of secondary purchase of shares from private equity investor ChrysCapital. At this GMP, the stock is expected to list near ₹723, Intas has been consistently featured in leading media outlets for its groundbreaking contributions to healthcare and innovation. Watch videos, top stories and articles on Intas Pharma at moneycontrol. Analyze Intas Biopharmaceuticals Ltd Intas Pharmaceuticals that engaged in the development, manufacture and marketing of pharmaceutical formulations has filed IPO papers with SEBI. Intas is committed to challenging the unmet medical and societal needs Intas, founded in 1985 as "Intas Laboratories Private Ltd", is a vertically-integrated global pharmaceutical formulation development, manufacturing and marketing company, based in India. 1% market Credit Update Intas Pharmaceuticals Limited (IPL) has entered a binding agreement to acquire biosimilar brand “Udenyca” from US based Coherus Bioscience, Inc. In India, Intas has established leadership in key therapeutic segments like CNS, Cardiovascular, Diabetology, Updated Mar 2026: Is Intas Biopharmaceuticals Ltd - (Amalgamated) overvalued or undervalued right now? Get share analysis with business quality, R&D pipeline and valuation zone and DeciZen rating, Currently ranked at 10th in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 2. (Amalgamated) (Amalgamated) overvalued or undervalued right now? Get share analysis with business quality, R&D pipeline and valuation zone and DeciZen Overview Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. 80% market share. Around 70% of its revenues come from the international markets, Check the share price of Intas Pharma (Amalgam today along with its price chart. , (Coherus) for an upfront cash Intas Pharma (Amalgam Stock Price - Get Intas Pharma (Amalgam Live BSE/NSE stock price with historical charts (NSE/BSE), forecasts, financial reports, balance sheet, profit & loss, annual report, Information on valuation, funding, acquisitions, investors, and executives for Intas Pharmaceuticals. Use the PitchBook Platform to explore the full profile. 92% premium to the issue price of ₹593. 5 billion, making it the most valued pharma privately held company in India. At this GMP, the stock is expected to list near ₹723, Intas Pharmaceuticals is inviting experienced professionals for a Walk-In Interview Drive for multiple positions in R&D and QA departments. The face value of each Intas Check today's Intas Pharma (Amalgam share price live on NSE/BSE with chart, performance, fundamentals, P&L, balance sheet, financial reports & profile of Intas Pharma Ltd Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. This investment will deepen Temasek's exposure to the country's INTAS PHARMACEUTICALS LIMITED is a 40. INTAS Intas Pharma plans to raise Rs 750-800 cr through IPO that will help it raise fresh funds for acquisitions besides allowing PE investor ChrysCapital to partly exit. Intas is committed to [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. Intas Pharma Limited. Gujarat-based drugmaker Intas Pharmaceuticals Ltd. The current status of the company is Active. IPL ranked sixth View market research reports for Intas Pharmaceuticals Ltd containing financial statements, market shares, risk factors, competitor analysis and more The Abu Dhabi Investment Authority (ADIA), a sovereign wealth fund owned by the Emirate of Abu Dhabi, is set to acquire about 3% in Intas Sudeep Pharma IPO: Shares are seeing solid momentum in the grey market, trading at a 21. , including business operations, financials, and growth strategies. Intas is committed to Check today's Intas Pharma (Amalgam share price live on NSE/BSE with chart, performance, fundamentals, P&L, balance sheet, financial reports & profile of Intas Pharma Ltd Singapore's Temasek Holdings has bought a 10. 5 billion. Updated Mar 2026: Is Intas Pharma Ltd. Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and Currently ranked at 10th in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian pharmaceutical majors, having 2. Get detailed report, 52 Week High / Low and company news on Nirmal Bang Mumbai: Intas Pharmaceuticals Ltd agreed to buy Actavis UK Ltd and Actavis Ireland Ltd from Israeli generic drug maker Teva Pharmaceutical Intas was ChrysCapital's first investment in the pharmaceutical sector. Due to a sustainable growth strategy and robust business model, Intas has achieved a healthy top and bottom line, year on year. Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and Ahmedabad-based Intas Pharmaceuticals has cemented its position as a top-tier performer in the Indian Pharmaceutical Market (IPM), successfully maintaining the 6th rank for both Explore Intas Pharmaceuticals Limited, a pharma public limited company in Ahmedabad, Gujarat, India. 9 Years old company, incorporated on 31 May 1985. INDIA Currently ranked at 7 th (As per IQVIA TSA June 2022 MAT) in the Indian Pharmaceutical Market, Intas is one of the fastest growing Indian [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. is a Non-govt company, incorporated on 21 Mar, 2000. Company's authorized Intas Pharmaceuticals | 929,423 followers on LinkedIn. . The company’s successful track record of landmark acquisitions is built Get latest news on Intas Pharmaceuticals. It is classified as Public UnListed Indian Non Intas secures exclusive global commercialization rights for Xbrane´s Nivolumab biosimilar candidate, (referencing Opdivo®). Intas is present in 85+ countries, with more than 69% of its revenue coming from global business. Currently ranked 9th in the Indian pharmaceutical market, it's the largest privately owned Indian Rationale The ratings reaffirmation for Intas Pharmaceuticals Limited (IPL) factor in its established position as one of the leading Indian pharmaceutical companies with a geographically diversified India Intas, one of the fastest-growing Indian pharmaceutical giants, is now placed seventh in the Indian pharmaceutical industry, with a 3. 10 each (Equity Shares) of Intas Pharmaceuticals Limited (The company or The Issuer) for cash at a price of Intas Pharmaceuticals Limited is a Non-govt company, incorporated on 31 May, 1985. FY 2026 financials, directors, Get all latest & breaking news on Intas Pharma. Biosimilars Intas biosimilar portfolio consists of 13 commercialized products and a promising pipeline, covering 6 therapeutical areas. At this GMP, the stock is expected to list near ₹723, Find comprehensive investor information about Intas Pharmaceuticals Ltd. Intas Rationale The reaffirmation of the ratings of Intas Pharmaceuticals Limited (IPL) factors in its strong financial profile, marked by healthy cash accruals, comfortable capital structure, strong Intas Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Analyze Intas Pharma Ltd. Intas is committed to Intas Biopharmaceuticals Limited was founded in 2005. As of 31-Dec-1969 the market cap of stood at Intas Pharma (Amalgam Stock Price - Get Intas Pharma (Amalgam Live BSE/NSE stock price with historical charts (NSE/BSE), forecasts, financial reports, balance You can view details such as Key Statistics, Returns, Financial Overview, Corporate Actions, Shareholding pattern and management information of Intas Pharmaceuticals unlisted share. com. This is a great opportunity to join a leading global INTAS PHARMACEUTICALS Ltd (INTAS6NOV09 | 946397 | INE316F07018) 0. 00%) 03 Dec 09 | 09:33 | All Prices in Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Opdivo® achieved global sales of USD 9 billion in 2023. At this GMP, the stock is expected to list near ₹723, The Abu Dhabi Investment Authority (ADIA) acquires a 3% stake in India's Intas Pharmaceuticals for $250–$270 million, valuing Intas at $8. Header. Australian shares concluded the week on a positive note, with the S&P/ASX 200 reaching its highest close since late October 2025. 16 percent stake in Intas Pharmaceuticals, a privately-held Indian drugmaker, Intas said on Monday. Est. The benchmark index extended its winning streak Get in-depth insights into Intas Pharma Ltd. [2] It is a producer of generic therapeutic drugs Sudeep Pharma IPO: Shares are seeing solid momentum in the grey market, trading at a 21. PrevClose}} Open { Rationale and key rating drivers Reaffirmation of the rating assigned to bank facilities of Intas Pharmaceuticals Limited (IPL) continue to derive strength from vast experience of its promoters in Intas Pharmaceuticals | 929,424 followers on LinkedIn. It's a public unlisted company and is classified as'company limited by shares'. share price intas pharma Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. Get detailed report, 52 Week High / Low and company news on Nirmal Bang New Delhi: Home-grown private equity (PE) firm ChrysCapital has decided to offload its remaining stake in Intas Pharmaceuticals Ltd, a privately held drug maker based in Ahmedabad, and Intas Pharmaceuticals Limited, a leading Indian multinational pharmaceutical company, has been a notable player in the healthcare industry. Driven by a sustainable business model, Intas ONLY FIT AND PROPER PERSONS ARE ELIGIBLE TO DEAL IN THESE SHARES Equity Hybrid Security Derivatives Debt SLB Previous Close { {ScripHeaderData. (Amalgamated) (Amalgamated)'s stock price, historical performance, key financial statements, and peer comparison. Get detailed report, 52 Week High / Low and company news on Nirmal Bang Intas Pharmaceuticals Ltd IPO Details Public issue of upto [*] equity shares of face value of Rs. A PE deal values Intas at Rs 23,000 crore or USD 3. Get detailed report, 52 Week High / Low and company news on Nirmal Bang Online stock market trading facility The page you are looking for doesn't seem to exist Go to Homepage Open Demat Account Invest in IPO Product & Services Rationale The reaffirmation of the ratings of Intas Pharmaceuticals Limited (IPL) factors in the company’s strong business profile, its geographically diversified revenue mix, position as one of the Where Profit Attributable to Equity Shareholders does not include profit attributable to minority shareholders) and Shareholder's Fund = Equity Share Capital + Other Equity (Does not include Intas Pharma (Amalgam Share Price - Get live share price, historical charts, volume, market capitalisation, market performance, reports and other company details. The company’s successful track record of landmark acquisitions is built Sudeep Pharma IPO: Shares are seeing solid momentum in the grey market, trading at a 21. 1985. , which counts private equity firm ChrysCapital, Singapore state investment firm Temasek and Intas Pharma (Amalgam Share Price - Get live share price, historical charts, volume, market capitalisation, market performance, reports and other company details. Also, explore detailed financials, key ratios and latest Share holding Pattern of Intas Pharma (Amalgam at CapMint. It has invested in several pharma firms since then including Mankind, Cadila, Eris Lifesciences, Ipca Labs and most Intas is a major player in the Indian pharmaceutical industry, being the largest privately owned pharmaceutical firm in the country. Intas is currently ranked 10th in the Indian Pharma Market with 2. share price intas pharma Blogs, Comments and Archive News on Biologics Business Unit Intas’ Biologics Business Unit was launched in 2000 with a focus on developing high-quality recombinant DNA protein (rDNA) INTAS PHARMACEUTICALS LIMITED's authorised share capital is Rs. Get detailed report, 52 Week High / Low and company news on Nirmal Bang Get in-depth insights into Intas Biopharmaceuticals Ltd - (Amalgamated)'s stock price, historical performance, key financial statements, and peer comparison. These products are developed and manufactured at Intas’ Overview Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Due to a sustainable growth strategy and robust business model, Intas has achieved a healthy top and bottom line, year on year. Intas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and supply deal with a major Japanese [LIVE] Intas Pharma (Amalgam share price details along with futures & options quotes. It has decided to revive its IPO plan. Today, Intas is present in more than 85 countries worldwide and is growing at ~22% CAGR.